Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Property, Plant & Equipment (Net)

Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.

Silence Therapeutics plcNASDAQ: SLN

Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026

Property, plant & equipment (net) falls 14.6% from a year ago

Property, plant & equipment (net) stood at $1.54M at the end of Q1 FY2026, down 14.6% from a year earlier and down 12.0% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.

Context

  • Property, plant & equipment (net) amounted to 1.3% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
  • Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.

What to watch

Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -14.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.54M-12.0% QoQ
Last fiscal yearDec 2025
$1.75M+10.8% YoY
Year agoMar 2025
$1.8M-14.6% since
Property, Plant & Equipment (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.6%——
1 year+10.8%——
3-year CAGR-7.4%——
5-year CAGR——
10-year CAGR——

Property, Plant & Equipment (Net) history

Mixed currencies · from the balance sheet

Latest · FY2025
1.75M USD
Year-over-year change
—

Property, Plant & Equipment (Net) vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -14.6% is the 4th highest of 8, against a peer median of -17.4%.
  • Property, plant & equipment (net) amounts to 1.3% of total assets for SLN, versus a peer median of 11.5%.
SLN Competitors
Property, Plant & Equipment (Net) for SLN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SRPTSarepta Therapeutics, Inc.Mar 2026$460.3M USD-9.3%+24.3%14.5%
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$429.65M USD+0.8%+8.6%24.7%
IONSIonis Pharmaceuticals, Inc.Sep 2026$390.09M USD+12.1%+12.3%13.4%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$26.5M USD-23.4%-14.8%10.8%
WVEWave Life Sciences Ltd.Mar 2026$18.07M USD-30.9%-23.4%3.1%
PRQRProQR Therapeutics N.V.Mar 2026€12.06M EUR-17.9%-8.1%12.2%
RNAAtrium Therapeutics, Inc.Mar 2026$6.38M USD——2.2%
SLNSilence Therapeutics plcMar 2026$1.54M USD-14.6%-7.4%1.3%
BNTCBenitec Biopharma Inc.Mar 2026$916K USD-17.4%-0.1%0.5%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —-17.4%-0.1%11.5%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Cash & Equivalents73.54M54.82M68.79M96.95M11.28M
Short-term Investments016.33M020.78M73.84M
Net Receivables331K915K23.98M21.5M24.61M
Inventory00000
Other Current Assets8.16M16.43M18.58M20.72M0
Total Current Assets86.33M96.69M103.15M149.72M118.66M
Property, Plant & Equipment (Net)1.94M2.2M2.31M1.58M1.75M
Goodwill7.59M8.01M9.98M7.51M10.62M
Intangible Assets24K320K362K249.32K288K
Long-term Investments301K284K000
Tax Assets00000
Other Non-current Assets003.65M2.87M127K
Total Non-current Assets9.86M10.81M16.3M12.2M12.78M
Total Assets96.19M107.5M119.45M161.92M131.44M
Account Payables4.07M3.19M3.35M2.95M4.41M
Short-term Debt00228K00
Tax Payables00475.5K715.98K0
Deferred Revenue006.57M244.52K168K
Other Current Liabilities4.43M9.45M8.58M2.75M5.94M
Total Current Liabilities15.17M21.94M22.34M13.44M13.61M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0075M41.38M55.45M
Other Non-current Liabilities72.5M63.49M000
Total Non-current Liabilities72.5M63.49M75.12M41.38M55.53M
Total Liabilities87.67M85.43M97.46M54.83M69.14M
Common Stock4.49M5.39M8.85M8.22M10.29M
Retained Earnings(222.97M)(263.26M)(431.89M)(378.8M)(562.57M)
Accumulated OCI42.67M53.27M40.36M(9.41M)(2.98M)
Other Stockholders Equity00(51.09M)00
Minority Interest00000
Total Equity8.53M22.07M21.99M107.1M62.3M
Total Debt137K446K346K93.49K160K
Net Debt(73.4M)(54.37M)(68.44M)(96.86M)(11.12M)

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.